| Number: 201109296 |
Principal Investigator: Moley, Jeffrey |
| Title: Multiple Endocrine Neoplasia and Medullary Thyroid Carcinoma Database and Tissue Repository |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |